Amgen Research (Munich) GmbH clinical trials
Acquired by Amgen, Mar 7, 2012 · source ↗
The registry lists 10 studies whose lead sponsor is Amgen Research (Munich) GmbH. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Feb 10, 2020.
Before and after it joined Amgen
- First submitted before Amgen Research (Munich) GmbH became part of Amgen
- 9
- First submitted after Amgen Research (Munich) GmbH became part of Amgen
- 1
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Amgen Research (Munich) GmbH10 studies
Something wrong with this grouping? Tell us on the Amgen page.
Studies
Recruiting first, then most recently updated. Showing 10 of 10. All Amgen studies →
- Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT01207388Phase 2
Sponsor listed in the registry: Amgen Research (Munich) GmbH · First submitted before Amgen Research (Munich) GmbH became part of Amgen
- Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT01466179Phase 2
Sponsor listed in the registry: Amgen Research (Munich) GmbH · First submitted before Amgen Research (Munich) GmbH became part of Amgen
- Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT01209286Phase 2
Sponsor listed in the registry: Amgen Research (Munich) GmbH · First submitted before Amgen Research (Munich) GmbH became part of Amgen
- Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic LeukemiaCompletedNCT01471782Phase 1/2
Sponsor listed in the registry: Amgen Research (Munich) GmbH · First submitted before Amgen Research (Munich) GmbH became part of Amgen
- Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)CompletedNCT01741792Phase 2
Sponsor listed in the registry: Amgen Research (Munich) GmbH · First submitted after Amgen Research (Munich) GmbH became part of Amgen
- Phase II Study of the BiTE® Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL)CompletedNCT00560794Phase 2
Sponsor listed in the registry: Amgen Research (Munich) GmbH · First submitted before Amgen Research (Munich) GmbH became part of Amgen
- Safety Study of the Bispecific T-cell Engager Blinatumomab (MT103) in Patients With Relapsed NHLCompletedNCT00274742Phase 1
Sponsor listed in the registry: Amgen Research (Munich) GmbH · First submitted before Amgen Research (Munich) GmbH became part of Amgen
- Phase I Study of MT110 in Lung Cancer (Adenocarcinoma and Small Cell), Gastric Cancer or Adenocarcinoma of the Gastro-Esophageal Junction, Colorectal Cancer, Breast Cancer, Hormone-Refractory Prostate Cancer, and Ovarian CancerCompletedNCT00635596Phase 1
Sponsor listed in the registry: Amgen Research (Munich) GmbH · First submitted before Amgen Research (Munich) GmbH became part of Amgen
- A Phase 1 Multiple Dose Study to Compare the Effects of AMG 223 and Sevelamer HCL (Renagel®)CompletedNCT00756860Phase 1
Sponsor listed in the registry: Amgen Research (Munich) GmbH · First submitted before Amgen Research (Munich) GmbH became part of Amgen
- Study of Adecatumumab Relative to FOLFOX After R0 Resection of Colorectal Liver MetastasesCompletedNCT00866944Phase 2
Sponsor listed in the registry: Amgen Research (Munich) GmbH · First submitted before Amgen Research (Munich) GmbH became part of Amgen